000			01667 a2200445 4500
005			20250518093330.0
264		0	_c20210427
008			202104s 0 0 eng d
022			_a1532-866X
024	7		_a10.1016/j.semarthrit.2020.02.011 _2doi
040			_aNLM _beng _cNLM
100	1		_avan Mulligen, E
245	0	0	_aThe impact of a disease flare during tapering of DMARDs on the lives of rheumatoid arthritis patients. _h[electronic resource]
260			_bSeminars in arthritis and rheumatism _c06 2020
300			_a423-431 p. _bdigital
500			_aPublication Type: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAntirheumatic Agents _xadministration & dosage
650	0	4	_aArthritis, Rheumatoid _xdrug therapy
650	0	4	_aDose-Response Relationship, Drug
650	0	4	_aDrug Tapering _xmethods
650	0	4	_aFemale
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMinimal Clinically Important Difference
650	0	4	_aPatient Reported Outcome Measures
650	0	4	_aPhysical Functional Performance
650	0	4	_aQuality of Life
650	0	4	_aSymptom Flare Up
650	0	4	_aTime Factors
650	0	4	_aTumor Necrosis Factor Inhibitors _xadministration & dosage
700	1		_aWeel, A E A M
700	1		_aKuijper, T M
700	1		_aHazes, J M W
700	1		_avan der Helm-van Mil, A H M
700	1		_ade Jong, P H P
773	0		_tSeminars in arthritis and rheumatism _gvol. 50 _gno. 3 _gp. 423-431
856	4	0	_uhttps://doi.org/10.1016/j.semarthrit.2020.02.011 _zAvailable from publisher's website
999			_c30791920 _d30791920